Osteolabs GmbH and labor team w ag Announce Sales Partnership for Switzerland and Liechtenstein
Tuesday, June 10, 2025
Osteolabs GmbH and labor team w ag have partnered to distribute the OsteoTest diagnostic across Switzerland and Liechtenstein. This advanced test, based on osteolabs’ CIM technology, provides early risk assessment and therapeutic monitoring for osteoporosis. The collaboration aims to bring cutting-edge calcium isotope diagnostics to a broader market, enhancing musculoskeletal health monitoring and supporting physicians with innovative solutions.
osteolabs GmbH, a German biotech company specializing in innovative diagnostic solutions for calcium-related metabolic disorders, and labor team, one of the leading medical laboratories in Switzerland, are pleased to announce a new strategic partnership.
Under the agreement, labor team w ag will distribute osteolabs’ flagship product, the OsteoTest, throughout Switzerland and Liechtenstein. OsteoTest is an advanced IVD diagnostic test for early risk assessment and therapeutic monitoring in patients with osteoporosis, based on osteolabs’ proprietary CIM (Calcium Isotope Marker) technology. Recent studies have demonstrated a strong correlation between CIM and various metabolic diseases that affect musculoskeletal health (Source). Moreover, CIM technology enables early and highly sensitive monitoring of transient changes in Bone Calcium Balance (BCaB)—a critical parameter of bone health—that cannot be reliably assessed using current standard methods (Source).
“We are excited to partner with labor team w ag, one of the leading medical laboratories in Switzerland and Liechtenstein, to make our CIM technology available to clinicians and patients in these regions,” said Dr. Michael Lutz. “This partnership helps us bring our advanced calcium isotope technology to a broader market.”
Priv.-Doz. Dr. Thomas Brinkmann, COO at labor team and Prof. Dr. Guido Funke, CMO at labor team added: “We are proud to integrate osteolabs’ pioneering OsteoTest into our diagnostic service offering. This test equips physicians with a powerful tool for early risk assessment and therapeutic monitoring of osteoporotic patients. According to the SVGO, over 500,000 patients in Switzerland are affected by osteoporosis.” (Source)
For more information about osteolabs and labor team, please visit:
www.osteolabs.de; https://www.linkedin.com/company/osteolabs-gmbh
www.laborteam.ch; https://www.linkedin.com/company/laborteam/
Contacts
osteolabs GmbH
Kathrin Hagen
[email protected]
+49 431 990 73 0
labor team w ag
Susanne Zwiker
[email protected]
+41 44 250 85 85
Source: biotechnewswire.ai
